It is anticipated that neurodegenerative diseases will be treated using strategies designed to increase the BDNF level [40] —the administration of recombinant proteins or drugs that activate its endogenous expression and gene therapy to relieve the symptoms of Alzheimer’s disease and Parkinson’s disease are now in trial. Here, BDNF is linked to early-onset autosomal dominant Alzheimer disease.